Anna Nicole Smith Possibly Died of Flu 'Cytokine Storm'
GenoMed® (Pink Sheets:GMED), a Next Generation
Disease Management company, announced today that Anna Nicole Smith
possibly died of a "cytokine storm" associated with the flu. GenoMed has
obtained excellent results against the "cytokine storm" for the past
five years, using already-existing blood pressure pills present in most
drugstores on earth. Ms. Smith's death may have been preventable.
Ms. Smith's attorney, Ron Rale, told The Associated Press that he had
talked to her on Tuesday or Wednesday, and she had flu symptoms and a
fever.
GenoMed recognized before anyone else that what kills healthy people
from a viral disease is the "cytokine storm" their own body creates to
fight the virus. For five years, GenoMed has been running free clinical
trials for West Nile virus encephalitis, regular influenza, and avian
influenza ("bird flu"). Its treatments are the subject of pending
patents.
Unfortunately, the public health authorities have been completely
uncooperative. For example, the CDC tried to shut down GenoMed's WNV
trial in June 2004. And the WHO has yet to respond to GenoMed about the
bird flu. Instead, the WHO has urged governments to stockpile Tamiflu at
the cost of billions of dollars, even though Tamiflu is known to have a
10% viral resistance rate. Since GenoMed targets the host's response,
rather than trying to kill the virus, there should be no viral
resistance.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer,
"We've found a novel approach to viral disease for the general
population. If the CDC and WHO hadn't ignored us for the past 5 years,
Anna Nicole Smith might have heard about us, used our approach to reduce
her flu symptoms, and still be alive. Every drugstore on earth carries
the drugs we use. And they're a lot safer than aspirin."
About GenoMed
Patients are encouraged to download GenoMed's approach to avian
influenza from its website, www.genomed.com.
GenoMed estimates that it can already save 10% of healthcare costs and
extend life by 5 years. Patients are encouraged to contact Dr. Moskowitz
(dwmoskowitz@genomed.com)
about joining GenoMed's Clinical Outcomes Improvement Program (COIP®).
Safe Harbor Statement
This press release contains forward-looking statements, including those
statements pertaining to GenoMed, Inc.'s (the Company's) finances and
treatments. The words or phrases "ought to," "should," "could," "may,"
or similar expressions are intended to identify "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from those
projected in the forward-looking statements as a result of a number of
risks and uncertainties, including but not limited to our research and
development being subject to scientific, economic, regulatory,
governmental, and technological factors. Statements made herein are as
of the date of this press release and should not be relied upon as of
any subsequent date. Unless otherwise required by applicable law, we
specifically disclaim any obligation to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.
See the original story at: http://eon.businesswire.com/releases/genomed/statement/prweb504146.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/Q291cC1IYWxmLVNpbmctSG9yci1NYWduLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
